Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8879 |
MR837
ZINC30303842,NSD2-PWWP1 antagonist 3f |
Others; Histone Methyltransferase | Chromatin/Epigenetic; Others |
MR837 (NSD2-PWWP1 antagonist 3f) 是可与人核受体结合 SET 结构域蛋白(PWWP 结构域) 结合的NSD2-PWWP1抑制剂。 | |||
T62705 |
NSD2-IN-1
|
||
NSD2-IN-1 (compound 38) 是一种有效的、高选择性的 NSD2-PWWP1(核受体结合 SET 结构域 2-PWWP1) 抑制剂,IC50为 0.11 μM。NSD2-IN-1 可以与 NSD2-PWWP1 结合,进而影响受 NSD2 调控的基因表达。NSD2-IN-1 可以诱导细胞凋亡 (apoptosis) 和细胞周期阻滞。 | |||
T79617 |
NSD2-IN-4
|
Histone Methyltransferase | Chromatin/Epigenetic |
NSD2-IN-4为选择性NSD2-SET抑制剂,显示出治疗与NSD2相关的疾病的潜在功效。 | |||
T9006 |
LEM-14
|
Others | Others |
LEM-14是一种强效的 NSD2特异性抑制剂(IC50:132μM)。LEM-14可能用于研究多发性骨髓瘤。 | |||
T9584 |
UNC6934
|
Others; Histone Methyltransferase | Chromatin/Epigenetic; Others |
UNC6934 是一种针对 NSD2 的 N 端 PWWP (PWWP1) 结构域的化学探针,可定位核仁。 | |||
T72979 |
LEM-14-1189
|
Histone Methyltransferase | Chromatin/Epigenetic |
LEM-14-1189 是一种 LEM-14 衍生物,是一种有效的核受体结合SET结构域 NSD 抑制剂,对 NSD1、NSD2、NSD3 具有抑制作用,IC50 分别为 418 μM 、111 μM 和 60 μM 。LEM-14-1189 具有潜在的抗癌活性,可用于研究多发性骨髓瘤 (MM)和血液系统疾病。 | |||
T12263L |
NSC305787 hydrochloride
(Rac)-NSC305787 hydrochloride |
Others | Others |
NSC305787 hydrochloride ((Rac)-NSC305787 hydrochloride) 是一种可透过细胞膜且具有选择性和有效性的小分子 Cdc25 dual specificity phosphatase 和 EZR 双重抑制剂,在胰腺癌细胞中显示出抗肿瘤活性,对Cdc25B2, Cdc25A,Cdc25B2 和 Cdc25C 具有抑制作用。NSC 663284 抑制 NSD2 (IC50 of 170 nM) 酶的活性。 | |||
T12083 |
MMSET-IN-1
|
Others | Others |
MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) . | |||
T79616 |
UNC7096
|
Histone Methyltransferase | Chromatin/Epigenetic |
UNC7096为一种选择性NSD2-PWWP1抑制剂,其Kd为46 nM,拥有潜在治疗NSD2相关疾病的能力。 | |||
T77967 |
MS159
|
PROTACs | PROTAC |
MS159为一有效的NSD2 (核受体结合SET结构域蛋白2) PROTAC降解剂,能够抑制肿瘤细胞生长,是探究NSD2在健康与疾病中作用的重要化学工具。 | |||
T83867 |
UNC8153 TFA
|
||
UNC8153 是一种 NSD2(组蛋白-赖氨酸 N-甲基转移酶)的降解剂,其通过诱导NSD2的降解,具有350 nM的50%降解常数(DC50)值,并且在20 µM浓度下对NSD2具有选择性,而不选择NSD1和NSD3。在MM.1S多发性骨髓瘤细胞中,UNC8153 (10 µM) 能够诱导NSD2降解并减少组蛋白H3赖氨酸36位二甲基化(H3K36me2),这一效应可以被泛素激活酶抑制剂MLN4924所抑制。它减少了表达带有在1099位上谷氨酸到赖氨酸激活突变的NSD2(NSD2E1099K)的MM.1S细胞的增殖,但在20 µM浓度下,对表达野生型NSD2的MDA-MB-231、U2OS或HEK293细胞无效。UNC8153 (20 µM) 降低了在迁移实验中MM.1S细胞的附着能力。 | |||
T10538 |
BI-9321
|
Others | Others |
BI-9321 is a selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist (Kd: 166 nM). BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2. | |||
T10538L |
BI-9321 trihydrochloride
|
Others | Others |
BI-9321 trihydrochloride is a selective and cellular active nuclear receptor-binding SET domain 3 (NSD3)-PWWP1 domain antagonist (Kd: 166 nM). BI-9321 is inactive against NSD2-PWWP1 and NSD3-PWWP2. | |||
T36802 |
Bisubstrate Inhibitor 78
|
||
Bisubstrate inhibitor 78 is an inhibitor of nicotinamide N-methyltransferase (NNMT; IC50= 1.41 μM).1It binds the NNMT active site in the binding pockets for the NNMT substrates S-adenosyl-L-methionine (SAM) and nicotinamide . Bisubstrate inhibitor 78 is selective for NNMT over histone-lysine N-methytransferase NSD2 and protein arginine methyltransferase 1 (PRMT1; IC50s = >50 μM for both). It reduces levels of 1-methylnicotinamide in, and inhibits proliferation of, HSC-2 oral cancer cells when us... | |||
T36978 |
AS-99 TFA
|
||
AS-99 TFA is a first-in-class, potent and selective ASH1L histone methyltransferase inhibitor (IC50= 0.79 μM, Kd= 0.89 μM) with anti-leukemic activity. AS-99 TFA blocks cell proliferation, induces apoptosis and differentiation, downregulates MLL fusion target genes, and reduces the leukemia burden in vivo[1]. AS-99 TFA is tested against a panel of 20 histone methyltransferases, including NSD1, NSD2, NSD3, and SETD2. NO significant inhibition is observed at 50 μM of AS-99 TFA on any of the tested... |